Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Benefits Of Grapefruit

International Groups Express Concern About Cambodian 'AIDS Colony'
In an open letter to Cambodia"s prime minister and health minister, more than 100 international HIV/AIDS advocates and human rights organizations "accused the Cambodian government of herding HIV-affected families into an "AIDS colony" outside the capital, Phnom Penh," the Guardian reports (McCurry, 7/28).
generic viagra online
Diabetes Experts Sound Caution Over Extended Role Of New Drugs, UK
MEDICAL experts have cautioned against indiscriminate use of new classes of medication for Britain"s increasing number of people with diabetes - saying the drug advances needed "careful adoption" to meet their full treatment potential.
News of the day
IQ Explains Some Of The Difference In Heart Disease Between People Of High And Low Socio-economic Status
A unique study looking at the difference in cardiovascular disease (heart disease and stroke) and life expectancy between people of high and low socio-economic status has found that a person"s IQ may have a role to play.
Nutrition

Sepracor Pharmaceuticals Ltd Withdraws Its Marketing Authorisation Application For Lunivia (eszopiclone)

The European Medicines Agency has been formally notified by Sepracor Pharmaceuticals Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Lunivia (eszopiclone), 2 and 3 mg tablets. Lunivia was expected to be used for the treatment of insomnia, including difficulty falling asleep, nocturnal awakening or early awakening in adults, usually for short-term duration. The application for the marketing authorisation for Lunivia was submitted to the Agency on 23 July 2007. In October 2008, Lunivia received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending that the medicine be granted a marketing authorisation. However, the CHMP recommended that the medicine should not be granted "new active substance" status. Following a re÷¬examination procedure at the request of the applicant, the CHMP confirmed its previous opinion in February 2009. At the time of withdrawal, the application was pending the adoption of a marketing authorisation decision by the European Commission. In its official letter, the company stated that the withdrawal of the application was based on the CHMP"s recommendation that Lunivia should not be regarded as containing a new active substance, and that the commercial viability of launching the product in the European Union was compromised. More information about Lunivia and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website after the next CHMP meeting of 26-29 May 2009. Notes 1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage. 2. The press release from the October 2008 meeting can be found here. 3. The summary of the positive opinion from October 2008 can be found here. EMEA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009